Schrodinger, Inc. · NASDAQ:SDGR
Schrodinger — Q1 2026 Earnings Presentation
9 slides from Schrodinger's earnings presentation, May 5, 2026
Slide 1: Schrödinger Reports First Quarter 2026 Financial Results
NEWS RELEASE Schrödinger Reports First Quarter 2026 Financial Results 2026-05-05 First Quarter ACV of $28 Million, Representing 12% Growth Continued Momentum in Transition to Hosted Software Licensing Schrödinger to Launch Bunsen, an Agentic AI Co-Scientist, This Summer Lilly’s Announced $2.3 Billio
Slide 2: First Quarter 2026 Operating and Financial Highlights
First Quarter 2026 Operating and Financial Highlights (comparisons are to rst quarter 2025, unless otherwise noted) ACV was $28.4 million, a 12% increase, and $201 million on a trailing four-quarter basis. Software revenue was $35.6 million, a 21% decrease, re ecting the company’s planned accelerate
Slide 3: Platform
Platform Today Schrödinger announced plans for release of an early-access version of Bunsen, its new agentic AI co- scientist, this summer. Bunsen autonomously executes complex molecular discovery work ows, expanding the user base and enhancing productivity across Schrödinger’s industry-leading comp
Slide 4: Webcast and Conference Call Information
malignancies, including a 100% response rate in patients with Waldenström macroglobulinemia (WM). SGR- 1505 has FDA Fast Track and Orphan Drug Designations for WM. In March, Structure Therapeutics, a collaborator and company co-founded by Schrödinger, announced positive topline results from its Phas
Slide 5: About Schrödinger
About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger’s software platform is built on more than 30 years of R&D investment and is licen
Slide 6: Forward-looking statements
Reform Act of 1995 including, but not limited to those statements regarding Schrödinger’s expectations about the speed and capacity of its computational platform, its nancial outlook for the scal year ending December 31, 2026, and second quarter ending June 30, 2026, its plans to continue to invest
Slide 7: Condensed Consolidated Statements of Operations
Condensed Consolidated Statements of Operations (Unaudited) (in thousands, except for share and per share amounts) Three Months Ended March 31, 2026 2025 Revenues: Software products and services $ 35,560 $ 44,972 Drug discovery 22,879 10,236 Contribution 148 4,343 Total revenues 58,587 59,551 Cost o
Slide 8: Condensed Consolidated Statements of Cash Flows
Total liabilities 320,639 362,107 Stockholders' equity: Preferred stock, $0.01 par value. Authorized 10,000,000 shares; zero shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively — — Common stock, $0.01 par value. Authorized 500,000,000 shares; 65,383,310 and 64,515,380
Slide 9: Jaren Madden (Investors and Media)
Net loss (GAAP) $ (60,026) $ (59,808) Change in fair value of equity investments 13,487 13,095 Other income (2,663) (4,204) Income tax expense 408 28 Depreciation and amortization 1,476 1,589 Stock-based compensation 9,073 11,574 Reorganization expense(a) 589 — Litigation and settlement expense(b) —